defoslimod   Click here for help

GtoPdb Ligand ID: 9024

Synonyms: OM 174 | OM-174
Immunopharmacology Ligand
Comment: Defoslimod is an analogue of lipopolysaccharide endotoxin-derived lipid A obtained from E. coli [1]. It was developed as an immunotherapeutic agent for the treatment of cancer. Defoslimod acts as an agonist of Toll-like receptors 2 and 4 (TLR2 and TLR4) [2].
We show the structure with chemical formula provided in the INN record for the compound (C52H100N2O20P2). PubChem CID 56841121, which claims to represent defoslimod has an extra carbon atom and two associated hydrogens (C53H102N2O20P2). But note also that the structure reported in [1] only has 51 carbon atoms.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 22
Hydrogen bond donors 11
Rotatable bonds 48
Topological polar surface area 366.48
Molecular weight 1134.63
XLogP 10.1
No. Lipinski's rules broken 4
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCCCCCCCCC(CC(=O)NC1C(OC(C(C1O)O)COC1OC(CO)C(C(C1NC(=O)CC(OC(=O)CCCCCCCCCCC)CCCCCCCCCCC)O)OP(=O)(O)O)OP(=O)(O)O)O
Isomeric SMILES CCCCCCCCCCC[C@H](CC(=O)N[C@H]1[C@H](O[C@@H]([C@H]([C@@H]1O)O)CO[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1NC(=O)C[C@@H](OC(=O)CCCCCCCCCCC)CCCCCCCCCCC)O)OP(=O)(O)O)OP(=O)(O)O)O
InChI InChI=1S/C52H100N2O20P2/c1-4-7-10-13-16-19-22-25-28-31-38(56)34-42(57)53-45-48(61)47(60)41(72-52(45)74-76(66,67)68)37-69-51-46(49(62)50(40(36-55)71-51)73-75(63,64)65)54-43(58)35-39(32-29-26-23-20-17-14-11-8-5-2)70-44(59)33-30-27-24-21-18-15-12-9-6-3/h38-41,45-52,55-56,60-62H,4-37H2,1-3H3,(H,53,57)(H,54,58)(H2,63,64,65)(H2,66,67,68)/t38-,39+,40-,41-,45-,46-,47-,48-,49-,50-,51-,52-/m1/s1
InChI Key GOWLTLODGKPXMN-MEKRSRHXSA-N
No information available.
Summary of Clinical Use Click here for help
OM-174 has completed a single Phase I clinical trial which was assessing its anti-tumour effect in patients with solid tumours (NCT01800812) [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01800812 Effects of OM-174 in Adult Patients With Solid Tumors Phase 1 Interventional Centre Hospitalier Universitaire Dijon